Plain-English translation of NCT07187635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a urine DNA test can help doctors make smarter decisions about repeat bladder cancer surgery. Right now, most patients with early-stage bladder cancer automatically get a second surgery a few weeks after their first one—even though many may not need it. This trial will compare two approaches: standard care (everyone gets the repeat surgery) versus a new approach where patients first get a urine test, and only those with positive results proceed to repeat surgery.
About three-quarters of newly diagnosed bladder cancers are caught early and haven't invaded the muscle layer, but they have a high risk of coming back. The repeat surgery is supposed to catch any remaining cancer, but many patients don't actually have residual disease—meaning they're undergoing an unnecessary procedure with its own risks, costs, and burden. This trial seeks to use a simple urine test to identify which patients truly need that second surgery and which ones can safely skip it.
You likely qualify if…
You likely don't qualify if…
After your initial bladder cancer surgery, you'll be randomly assigned to either standard care or the new urine-test approach. If you're in the urine-test group, you'll provide a urine sample 2–6 weeks after your first surgery—a simple, non-invasive procedure. Based on that test result, your doctor will either recommend a repeat surgery or move forward with standard monitoring and treatment without another operation. Either way, you'll continue with regular follow-up care as recommended for bladder cancer patients.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China